Jazz Pharmaceuticals Shares Outstanding 2007-2018 | JAZZ

Jazz Pharmaceuticals shares outstanding history from 2007 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Jazz Pharmaceuticals shares outstanding for the quarter ending June 30, 2018 were 0.061B, a 0.04% decline year-over-year.
  • Jazz Pharmaceuticals 2017 shares outstanding were 0.061B, a 0.89% decline from 2016.
  • Jazz Pharmaceuticals 2016 shares outstanding were 0.062B, a 1.85% decline from 2015.
  • Jazz Pharmaceuticals 2015 shares outstanding were 0.063B, a 0.67% increase from 2014.
Jazz Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2017 61
2016 62
2015 63
2014 63
2013 62
2012 60
2011 47
2010 39
2009 30
2008 26
2007 14
2006 0
2005 0
Jazz Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 61
Q1 2018 61
Q4 2017 61
Q3 2017 61
Q2 2017 61
Q1 2017 61
Q4 2016 62
Q3 2016 62
Q2 2016 62
Q1 2016 63
Q4 2015 63
Q3 2015 63
Q2 2015 63
Q1 2015 63
Q4 2014 63
Q3 2014 63
Q2 2014 62
Q1 2014 59
Q4 2013 62
Q3 2013 62
Q2 2013 62
Q1 2013 62
Q4 2012 60
Q3 2012 61
Q2 2012 61
Q1 2012 58
Q4 2011 47
Q3 2011 47
Q2 2011 47
Q1 2011 46
Q4 2010 39
Q3 2010 42
Q2 2010 35
Q1 2010 35
Q4 2009 30
Q3 2009 31
Q2 2009 29
Q1 2009 29
Q4 2008 26
Q3 2008 27
Q2 2008 24
Q1 2008 24
Q4 2007 14
Q3 2007 24
Q2 2007 8
Q1 2007 0
Q4 2006 0
Q3 2006 13
Q2 2006 0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $9.782B $1.619B
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.
Stock Name Country Market Cap PE Ratio
Shire (SHPG) Ireland $54.150B 11.47
Zoetis (ZTS) United States $42.969B 31.18
Tilray (TLRY) United States $14.435B 0.00
Grifols (GRFS) Spain $14.360B 18.61
Neurocrine Biosciences (NBIX) United States $10.880B 0.00
Nektar Therapeutics (NKTR) United States $10.060B 11.76
Impax Laboratories (AMRX) United States $7.002B 37.24
Sage Therapeutics (SAGE) United States $6.858B 0.00
Ionis Pharmaceuticals (IONS) United States $6.776B 0.00
Catalent (CTLT) United States $6.212B 26.80
United Therapeutics (UTHR) United States $5.498B 7.06
FibroGen (FGEN) United States $4.837B 0.00
Loxo Oncology (LOXO) United States $4.802B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.893B 15.07
Endo (ENDP) Ireland $3.569B 5.13
Madrigal Pharmaceuticals (MDGL) United States $3.186B 0.00
USANA Health Sciences (USNA) United States $3.010B 26.52
Heron Therapeutics (HRTX) United States $2.659B 0.00
Ironwood Pharmaceuticals (IRWD) United States $2.648B 0.00
Aerie Pharmaceuticals (AERI) United States $2.557B 0.00
Xencor (XNCR) United States $2.536B 0.00
PTC Therapeutics (PTCT) United States $2.372B 0.00
Spectrum Pharmaceuticals (SPPI) United States $2.163B 0.00
TESARO (TSRO) United States $1.964B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.960B 0.00
Portola Pharmaceuticals (PTLA) United States $1.868B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.762B 21.55
Zogenix (ZGNX) United States $1.743B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.658B 0.00
Corcept Therapeutics (CORT) United States $1.655B 25.46
Tricida (TCDA) United States $1.496B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.488B 0.00
TherapeuticsMD (TXMD) United States $1.417B 0.00
ImmunoGen (IMGN) United States $1.347B 0.00
Esperion Therapeutics (ESPR) United States $1.267B 0.00
Endocyte (ECYT) United States $1.264B 0.00
Karyopharm Therapeutics (KPTI) United States $1.125B 0.00
Radius Health (RDUS) United States $0.796B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.782B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.760B 0.00
Flexion Therapeutics (FLXN) United States $0.749B 0.00
Dova Pharmaceuticals (DOVA) United States $0.698B 0.00
GlycoMimetics (GLYC) United States $0.628B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.586B 0.00
ChemoCentryx (CCXI) United States $0.566B 33.88
OptiNose (OPTN) United States $0.563B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.549B 0.00
ArQule (ARQL) United States $0.546B 0.00
Siga Technologies (SIGA) United States $0.531B 0.00
Odonate Therapeutics (ODT) United States $0.519B 0.00
CASI Pharmaceuticals (CASI) United States $0.497B 0.00
Xeris Pharmaceuticals (XERS) United States $0.495B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.485B 0.00
Collegium Pharmaceutical (COLL) United States $0.472B 0.00
Translate Bio (TBIO) United States $0.467B 0.00
Aclaris Therapeutics (ACRS) United States $0.464B 0.00
Dermira (DERM) United States $0.456B 0.00
Akebia Therapeutics (AKBA) United States $0.444B 0.00
Minerva Neurosciences (NERV) United States $0.430B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.425B 28.97
Verrica Pharmaceuticals (VRCA) United States $0.423B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.419B 0.00
Forty Seven (FTSV) United States $0.418B 0.00
ElectroCore (ECOR) United States $0.410B 0.00
Aquestive Therapeutics (AQST) United States $0.401B 0.00
Mast Therapeutics (SVRA) United States $0.394B 0.00
Zafgen (ZFGN) United States $0.382B 0.00
Depomed (ASRT) United States $0.376B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.340B 0.00
MEI Pharma (MEIP) United States $0.323B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.318B 0.00
Concert Pharmaceuticals (CNCE) United States $0.314B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.306B 0.00
Opexa Therapeutics (ACER) United States $0.298B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.292B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.272B 0.00
Affimed (AFMD) Germany $0.271B 0.00
Aratana Therapeutics (PETX) United States $0.260B 0.00
IMV INC (IMV) Canada $0.251B 0.00
Melinta Therapeutics (MLNT) United States $0.249B 0.00
Neon Therapeutics (NTGN) United States $0.247B 0.00
Galectin Therapeutics (GALT) United States $0.246B 0.00
Ocular Therapeutix (OCUL) United States $0.242B 0.00
Ardelyx (ARDX) United States $0.242B 0.00
Tyme Technologies (TYME) United States $0.228B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.227B 0.00
Jounce Therapeutics (JNCE) United States $0.220B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.212B 0.00
KalVista Pharmaceuticals (KALV) United States $0.202B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.201B 0.00
Achaogen (AKAO) United States $0.194B 0.00
Zomedica Pharmaceuticals (ZOM) United States $0.189B 0.00
Lannett Co Inc (LCI) United States $0.185B 1.53
DURECT (DRRX) United States $0.183B 0.00
MediWound (MDWD) Israel $0.175B 0.00
Nature's Sunshine Products (NATR) United States $0.172B 0.00
Calithera Biosciences (CALA) United States $0.171B 0.00
Redhill Biopharma (RDHL) Israel $0.170B 0.00
Aldeyra Therapeutics (ALDX) United States $0.165B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.158B 0.00
Adherex Technologies (FENC) United States $0.157B 0.00
Cardiome Pharma (CORV) Canada $0.155B 0.00
Immune Design (IMDZ) United States $0.154B 0.00
Recro Pharma (REPH) United States $0.154B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.153B 0.00
Neos Therapeutics (NEOS) United States $0.147B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.142B 0.00
Champions Oncology (CSBR) United States $0.137B 0.00
ProNAi Therapeutics (SRRA) Canada $0.136B 0.00
ContraFect (CFRX) United States $0.133B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.128B 0.00
Forward Pharma (FWP) Denmark $0.122B 0.00
Infinity Pharmaceuticals (INFI) United States $0.121B 0.00
Iterum Therapeutics (ITRM) Ireland $0.120B 0.00
Rafael Holdings (RFL) United States $0.115B 0.00
Molecular Templates (MTEM) United States $0.111B 0.00
CTI BioPharma (CTIC) United States $0.109B 0.00
BioLineRx (BLRX) Israel $0.096B 0.00
Trillium Therapeutics (TRIL) Canada $0.091B 0.00
Nivalis Therapeutics (ALPN) United States $0.090B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.087B 0.00
Actinium Pharmaceuticals (ATNM) United States $0.080B 0.00
KemPharm (KMPH) United States $0.080B 0.00
Otonomy (OTIC) United States $0.080B 0.00
Novan (NOVN) United States $0.074B 0.00
Natural Alternatives (NAII) United States $0.073B 9.32
Opiant Pharmaceuticals (OPNT) United States $0.060B 50.40
SCYNEXIS (SCYX) United States $0.059B 0.00
Ampio Pharmaceuticals (AMPE) United States $0.055B 0.00
Mannatechorporated (MTEX) United States $0.048B 25.44
Tokai Pharmaceuticals (NVUS) United States $0.046B 0.00
India Globalization Capital (IGC) United States $0.044B 0.00
Heat Biologics (HTBX) United States $0.044B 0.00
Capnia (SLNO) United States $0.043B 0.00
Genocea Biosciences (GNCA) United States $0.043B 0.00
Onconova Therapeutics (ONTX) United States $0.043B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.040B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.038B 0.00
Avenue Therapeutics (ATXI) United States $0.037B 0.00
ProPhase Labs (PRPH) United States $0.035B 3.90
Lipocine (LPCN) United States $0.033B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.032B 0.00
IsoRay (ISR) United States $0.032B 0.00
Biomerica (BMRA) United States $0.030B 0.00
NanoViricides (NNVC) United States $0.028B 0.00
Jaguar Animal Health (JAGX) United States $0.028B 0.00
Can-Fite Biopharma (CANF) Israel $0.026B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.026B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.025B 0.00
HANCOCK JAFFE (HJLI) United States $0.025B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.023B 0.00
Xenetic Biosciences (XBIO) United States $0.023B 0.00
Midatech Pharma (MTP) United Kingdom $0.022B 0.00
Citius Pharmaceuticals (CTXR) United States $0.022B 0.00
Cyanotech (CYAN) United States $0.021B 0.00
Shineco (TYHT) China $0.021B 1.82
Regulus Therapeutics (RGLS) United States $0.020B 0.00
Egalet (EGLT) United States $0.019B 0.00
Aradigm (ARDM) United States $0.018B 0.00
Aviragen Therapeutics (VXRT) United States $0.018B 0.00
ESSA Pharma (EPIX) Canada $0.018B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.018B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.015B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.015B 0.00
Skyline Medical (AIPT) United States $0.014B 0.00
Bio-Path Holdings (BPTH) United States $0.012B 0.00
OncoGenex Pharmaceuticals (ACHV) United States $0.012B 0.00
Intellipharmaceutics (IPCI) Canada $0.011B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.011B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.008B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.007B 0.00
Pain Therapeutics (PTIE) United States $0.007B 0.00
Apricus Biosciences (APRI) United States $0.007B 0.00
PharmAthene (ALT) United States $0.005B 0.00
RXi Pharmaceuticals (RXII) United States $0.005B 0.00
Biostar Pharmaceuticals (BSPM) China $0.005B 2.69
Bio Blast Pharma (ORPN) Israel $0.004B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.002B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00